A whistle-blower lawsuit accuses Walgreen executives of encouraging pharmacists to switch patients' Zantac tablet prescriptions to a Par Pharmaceuticals capsule version that cost up to three times as much. Par representatives alerted Walgreen managers that Medicaid limited reimbursement for the tablet version but not for the capsule version. Walgreen's director of pharmacy marketing allegedly told pharmacists that substituting the easier-to-swallow capsules for the tablets was "a unique opportunity" to interact with patients.

Full Story:

Related Summaries